Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IMTVO14,Naltrexone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Immgenuity
Deal Size : Undisclosed
Deal Type : Collaboration
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
Details : The joint research will focus on using Immgenuity’s IMTV014 and Biostax’s Lodonal™ and JKB-122 both independently and together to determine if the immune modulatory effects of Biostax’s drug therapies combined with Immgenuity’s IMTV014 can achi...
Brand Name : IMTVO14
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 29, 2023
Lead Product(s) : IMTVO14,Naltrexone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Immgenuity
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?